MAPT and Alzheimer disease: To confirm whether 2D6-2C6 recognizes tau aggregates in human subjects, we investigated the immunoreactivity of 2D6-2C6 using paraffin sections from two AD cases with Braak’s NFT stage V and a healthy control (Supplemental Table 1).